SecBot SecBot
425 ·Filed May 26, 2026

XOMAP

XOMA Royalty Corp
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001193125-26-238267
Rule 425 M&A communications
Actionable Insight ▲ Bullish

The filing confirms deal progression with no adverse changes. The key catalyst is the stockholder vote, which is virtually assured given BVF's 43.3% support. Monitor for HSR clearance and any potential competing bids before the vote. The CVR component is speculative and may take years to resolve.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$25.36
T+0 close · May 26, 2026 · via day close
Latest settled
+0.47%
T+20 · $25.48
Vs SPY
+2.42%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · May 26 $25.36entry
  2. T+1 · 6mo ago +0.27%α +0.32% · $25.43
  3. T+5 · 6mo ago +0.09%α −1.00% · $25.38
  4. T+20 · 5mo ago +0.47%α +2.42% · $25.48
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

XOMA Royalty filed its preliminary proxy statement/prospectus on Form S-4 with the SEC in connection with the proposed acquisition by Ligand Pharmaceuticals. The filing confirms the all-cash deal at $39.00 per share plus one contingent value right (CVR) tied to the Janssen Litigation, with a special stockholder meeting to vote on the merger and holding company reorganization. No changes to deal terms were disclosed; this filing advances the deal toward the expected Q3 2026 close.

Key Financial Metrics

Deal Value
$739.0M
Premium
29%
Deal Type
merger

Key Facts

  • Ligand to acquire XOMA Royalty for $39.00 per share in cash plus one CVR per share tied to the Janssen Litigation
  • Deal valued at approximately $739 million for the cash portion
  • Special stockholder meeting to be held to vote on merger and holding company reorganization
  • BVF Partners, holding ~43.3% of XOMA common stock, has agreed to vote in favor via Support Agreements
  • Perpetual Preferred Stock (Series A and B) to be redeemed prior to closing
  • Closing expected in Q3 2026, subject to stockholder and HSR approvals
  • Termination fee of $40.0 million payable by XOMA under certain circumstances

Financial Impact

$39.00 per share cash consideration plus CVR; total cash consideration ~$739M based on ~18.9M fully diluted shares

share pricedeal value

Risk Factors

  • Stockholder approval still required, though BVF's 43.3% support makes failure unlikely
  • HSR waiting period must expire or be terminated
  • Janssen Litigation may yield no recovery, making CVRs worthless
  • Litigation challenging the merger could delay or prevent closing
  • If deal fails, XOMA must pay $40M termination fee and faces operational uncertainty

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
60% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001193125-26-238267
Document: 0001193125-26-238267-index-headers.html0001193125-26-238267
Document: 0001193125-26-238267-index.html0001193125-26-238267
Document: 0001193125-26-238267.txt0001193125-26-238267

Track record

6 reports on XOMAP

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +0.44% at T+20 after the Apr 27, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Jun 10, 202622w ago DEFM14A Bullish 8/10 Entry $25.51 to $24.98 ▼ −2.07% −3.96% vs SPY
  2. May 26, 202624w ago 425 Bullish 7/10 Viewing Entry $25.36 to $25.48 ▲ +0.47% +2.42% vs SPY
  3. May 18, 202626w ago DEFA14A Neutral 4/10 Entry $25.38 to $25.40 ▲ +0.08% −1.50% vs SPY
  4. Apr 27, 202629w ago DEFA14A Bullish 8/10 Entry $25.25 to $25.36 ▲ +0.44% −4.52% vs SPY
  5. Apr 27, 202629w ago 8-K Bullish 8/10 Entry $25.25 to $25.36 ▲ +0.44% −4.52% vs SPY
  6. Mar 30, 202633w ago DEFA14A Neutral 3/10 Entry $25.74 to $25.62 ▼ −0.47% −9.89% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 8h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026